
Odyssey Investment Partners to Sell Applied Technical Services to SGS for $1.325 Billion
ATS has a nearly 60-year history of providing critical solutions to clients across a diverse set of large and stable end markets including manufacturing, power generation, food and beverage, chemicals, aerospace, life sciences, and defense. Its market-leading service offerings include materials testing, environmental simulation, chemical analysis, calibration, non-destructive inspection, and forensic consulting. ATS is headquartered in Marietta, Georgia and employs approximately 2,100 team members in over 85 locations across the United States.
ATS has undergone a dramatic transformation since it was acquired by an Odyssey fund in 2020. During this time, the Company completed nearly 40 acquisitions, through which it added considerable scale and diversified its service offerings and end markets. Further, Odyssey constructed a world-class executive team that has driven the Company forward and built out a centralized corporate structure that has enhanced efficiency across ATS's footprint.
Jonathan Place, a Managing Principal at Odyssey, said, "We are very proud of our highly successful investment in ATS. In partnership with the management team, we have built an unparalleled North American business in terms of scale and diversity, and one that is regarded by its customers as a best-in-class service provider. As a result of our many accomplishments, ATS is well positioned for continued long-term growth and strong performance, and has attracted the interest of the global leader, which envisions it as a critical piece in achieving its considerable ambitions in North America. In addition, the strength and size of the SGS network will provide greater opportunities for ATS to expand its services to new geographies. We are grateful to the management team for their hard work and dedication and wish all of ATS's employees continued success as part of SGS.'
ATS CEO Mike McIlwain added, 'Odyssey has been an exceptional partner to ATS over the past four years. Under its ownership, our business achieved unprecedented growth as a result of the team's vision, industry experience, and the considerable financial and strategic resources they made available to us. I want to thank the entire ATS team for their tireless efforts and commitment to realizing this vision. Together with Odyssey, we've built upon our strong brand and service culture, which has further strengthened our loyal customer relationships. As we move on to a new chapter, we thank Odyssey for our collaboration, the benefits of which will be felt for years to come.'
Completion of the transaction, which is expected by the end of 2025, is subject to customary closing conditions.
Houlihan Lokey is serving as lead financial advisor with Rothschild & Co. as co-financial advisor, and Latham & Watkins LLP is serving as legal counsel to Odyssey.
About Odyssey Investment Partners
Odyssey Investment Partners is a leading private equity investment firm with more than a 25-year history of partnering with skilled managers and using its buy, build and integrate approach to transform middle-market companies into more efficient and diversified businesses with strong growth profiles. Odyssey makes primarily majority-controlled investments in industrial and business services sectors with a long-term positive outlook and favorable secular trends. For further information about Odyssey, please visit www.odysseyinvestment.com.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
U.S. Leads North America Syringe Infusion Pumps Market Amid Rising Hospitalizations and Chronic Diseases
The North America Syringe Infusion Pumps Market is projected to grow from USD 645.1 million in 2024 to USD 1.04 billion by 2030, at a CAGR of 8.40%. Key drivers include an increase in chronic diseases and surgeries, technological advancements, and the expansion of home healthcare. The market is bolstered by favorable regulations and major regional growth. North American Syringe Infusion Pumps Market Dublin, July 04, 2025 (GLOBE NEWSWIRE) -- The "North America Syringe Infusion Pumps Market Size, Share & Trends Analysis Report by Disease Indication (Pediatrics/neonatology, Chemotherapy, Diabetes, Gastroenterology), End-use (Hospitals, Homecare), Country with Growth Forecasts, 2025-2030" report has been added to North America Syringe Infusion Pumps Market was valued at USD 645.1 million in 2024, and is projected to reach USD 1.04 billion by 2030, rising at a CAGR of 8.40%. The market is experiencing substantial growth driven by the increasing prevalence of chronic diseases, affecting approximately six in ten adults and necessitating precise, continuous medication delivery for conditions such as cancer and diabetes. The rising number of surgical procedures and ICU admissions further amplifies demand for these pumps, crucial for delivering anesthetics and critical care medications. This is especially true considering the projected increase in U.S. hospitalizations from 36 million in 2025 to 40 million by advancements in smart infusion technologies, including Dose Error Reduction Systems (DERS) and EHR compatibility, are pivotal in enhancing medication safety and efficiency, as North America leads in their adoption. The expanding home healthcare and ambulatory care sectors, fueled by an aging population and cost-containment strategies, are increasing the demand for portable, user-friendly syringe pumps for safe medication delivery outside hospitals. Favorable regulatory environments and reimbursement policies further support the sustained growth and innovation within the America Syringe Infusion Pumps Market Report Highlights: Pediatrics/neonatology held the largest revenue share of over 25% in 2024, owing to the critical need for precise drug delivery for newborns and infants, coupled with advancements in safety technologies and NICU/PICU investments The chemotherapy segment is projected to grow at the fastest CAGR over the forecast period Market growth is fueled by the critical need for precise syringe pump delivery of potent drugs, supported by safety features, and the increasing number of cancer cases. Hospitals dominated the market with around 40.0% of the total revenue share in 2024 due to high demand for precise drug delivery in critical care and diverse applications. Homecare is projected to grow at the fastest CAGR of 8.7% over the forecast period. The U.S. dominated the North American syringe infusion pumps market, supported by the high prevalence of chronic diseases and growing national healthcare expenditure. Companies Featured The major companies featured in this North America Syringe Infusion Pumps market report include: Baxter B. Braun Medical Inc. Fresenius Kabi AG ICU Medical, Inc. Micrel Medical Devices SA Boston Scientific Corporation BD Terumo Corporation Moog Inc. IRadimed Corporation CODAN Companies ACROMED Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $645.1 Million Forecasted Market Value (USD) by 2030 $1040 Million Compound Annual Growth Rate 8.4% Regions Covered North America Key Topics Covered: Chapter 1. Methodology and ScopeChapter 2. Executive Summary2.1. Market Outlook2.2. Segment Outlook2.3. Competitive InsightsChapter 3. North America Syringe Infusion Pumps Market Variables, Trends & Scope3.1. Market Lineage Outlook3.2. Market Dynamics3.3. North America Syringe Infusion Pumps Market Analysis Tools3.3.1. Industry Analysis - Porter's3.3.2. PESTEL AnalysisChapter 4. North America Syringe Infusion Pumps Market: Disease Indication Estimates & Trend Analysis4.1. Disease Indication Segment Dashboard4.2. North America Syringe Infusion Pumps Market: Disease Indication Movement Analysis4.3. North America Syringe Infusion Pumps Market Size & Trend Analysis, by Disease Indication, 2018 to 2030 (USD Million)4.4. Chemotherapy4.5. Diabetes4.6. Gastroenterology4.7. Analgesia/Pain Management4.8. Pediatrics/Neonatology4.9. Hematology4.10. OthersChapter 5. North America Syringe Infusion Pumps Market: End Use Estimates & Trend Analysis5.1. End Use Segment Dashboard5.2. North America Syringe Infusion Pumps Market: End Use Movement Analysis5.3. North America Syringe Infusion Pumps Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)5.4. Hospitals5.5. Homecare5.6. Others (ASC, Nursing Homes, Rehabilitation Centers)Chapter 6. North America Syringe Infusion Pumps Market: Country Estimates & Trend Analysis6.1. Country Market Dashboard6.2. Country Market Share Analysis, 2024 & 20306.3. North America Syringe Infusion Pumps Market by country: Key Takeaways6.4. U.S.6.5. Canada6.6. MexicoChapter 7. Competitive Landscape7.1. Recent Developments & Impact Analysis, By Key Market Participants7.2. Company/Competition Categorization7.3. Vendor Landscape7.3.1. Key company heat map analysis, 20247.4. Company Profiles Baxter B. Braun Medical Inc. Fresenius Kabi AG ICU Medical, Inc. Micrel Medical Devices SA Boston Scientific Corporation BD Terumo Corporation Moog Inc. IRadimed Corporation CODAN Companies ACROMED For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment North American Syringe Infusion Pumps Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Hypebeast
8 hours ago
- Hypebeast
Stellantis Revives SRT Performance Division Under Tim Kuniskis
Summary Stellantishas officially revived its iconic Street and Racing Technology (SRT) division, appointing Tim Kuniskis to lead the reborn performance arm while also taking on a newly created role overseeing American brands and North America marketing and retail strategy. Kuniskis will retain his position as CEO ofRam, and continue shaping the performance future ofChrysler,Dodge,Jeep, and Ram. The return of SRT signals a renewed focus on high-performance engineering across Stellantis' American brands. 'We're getting the band back together,' said Kuniskis, who emphasized assembling top talent in powertrain and vehicle dynamics to deliver the kind of power, handling and innovation that defines the SRT name. The division will also oversee Direct Connection, North American motorsports efforts and initiatives like Ram's return to the NASCAR Truck Series in 2026. With this move, Stellantis aims to unify its performance strategy and reignite enthusiasm among loyal fans. According to Stellantis COO Antonio Filosa, the company is counting on Kuniskis' 'strategic mindset and competitive spirit' to build deeper connections with customers through bold performance products and experiences.


Business Wire
21 hours ago
- Business Wire
AM Best Affirms Credit Ratings of Trisura Group Ltd. Members
OLDWICK, N.J.--(BUSINESS WIRE)-- AM Best has affirmed the Financial Strength Rating (FSR) of A- (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of 'a-' (Excellent) of Trisura Specialty Insurance Company (TSIC), Trisura Insurance Company (TIC), Bricktown Specialty Insurance Company (BSIC) and Trisura Guarantee Insurance Company (TGIC). Concurrently, AM Best has affirmed the FSR of A- (Excellent) and the Long-Term ICR of 'a-' (Excellent) of First Founders Assurance Company (FFAC) (Chester, NJ). The aforementioned companies are subsidiaries of Trisura Group Ltd. (TGL) [TSX: TSU] (Toronto, Ontario, Canada), a non-operating holding company. TSIC, TIC, and BSIC are domiciled in Oklahoma City, OK, while TGIC is domiciled in Toronto, Ontario, Canada. The outlook of these Credit Ratings (ratings) is stable. The ratings reflect TGL's overall balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, neutral business profile and appropriate enterprise risk management (ERM). The ratings acknowledge improvement in TGL's overall balance sheet strength assessment, supported by the strongest level of risk-adjusted capitalization, as measured by Best's Capital Adequacy Ratio (BCAR). Additionally, the group's capital base has grown significantly over the recent five-year period, driven by several public capital raises and very strong earnings growth, which more than tripled in the recent three-year period. This growth in equity has supported the group's overall growth and its expansion into the admitted U.S. market. While underwriting leverage was previously elevated due to an accelerated growth period, recent moderation in premium growth, combined with capital expansion, has resulted in leverage metrics that closely align with industry norms. Financial flexibility is strong with moderate levels of debt and very strong interest coverage. TGL's operating performance benefits from the diversification in its earnings from fronting fee income, underwriting income and investment income and its business profile recognizes the diversification afforded by its diversified North American footprint, providing specialty insurance in the surety, warranty, corporate insurance, program and fronting business lines. The ratings of FFAC reflect its balance sheet strength, which AM Best assesses as very strong, as well as its adequate operating performance, limited business profile and appropriate ERM. The ratings acknowledge the significant capital and operational support FFAC receives from TGL and its strategic importance to TGL's U.S. surety operations. In the second quarter of 2024, TGL contributed approximately USD $55 million of capital to FFAC. Furthermore, TGL seeks to continue to expand FFAC's licensing to all 50 states. This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.